Company Overview of The Global Alliance for TB Drug Development
The Global Alliance for TB Drug Development is a non-profit organization.
Key Executives for The Global Alliance for TB Drug Development
President of Stakeholders Association and Director
Head of Project Management
Compensation as of Fiscal Year 2014.
The Global Alliance for TB Drug Development Key Developments
The Global Alliance for TB Drug Development Appoints Willo Brock as Senior Vice President, External Affairs
Jul 31 14
The Global Alliance for TB Drug Development (TB Alliance) announced the appointment of Willo Brock as Senior Vice President, External Affairs. Mr. Brock comes to TB Alliance having most recently served as Head of Major Donor Relations for WWF International (formerly known as the World Wildlife Fund). In his role, Mr. Brock will guide the TB Alliance's resource development, advocacy and policy, and community and stakeholder engagement strategies, which are focused on building global support for the development of promising new treatments to fight tuberculosis (TB). Mr. Brock comes to the TB Alliance with nearly 20 years of experience in international development, and has worked in more than 60 countries around the world. At WWF International, he led major donor relations for the $100 million Campaign for a Living Planet.
Sanofi and The Global Alliance for TB Drug Development Announce Collaboration to Accelerate New Treatments Against Tuberculosis
Sep 20 12
Sanofi and The Global Alliance for TB Drug Development announced a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB). Under the agreement, Sanofi and TB Alliance will collaborate to further optimize and develop several novel compounds in Sanofi's library that have demonstrated activity against Mycobacterium tuberculosis, the bacterium that causes tuberculosis. This includes in-depth research of lead compounds based upon identified chemical derivatives of natural products, which have promising potential to treat all forms of tuberculosis, and the chemical optimization of other series of compounds that have been identified as hits through high-throughput screening.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries